Emisar Pharma Services News Today

Welcome to Competition Currents, a monthly newsletter for Greenberg Traurig clients and colleagues highlighting significant recent developments in global antitrust and competition law.

Commission pauses major biopharma transaction involving drugs priced in the hundreds of thousands of dollars. As part of the Federal Trade Commissions promised campaign to protect competition in the...

We noted that the Inflation Reduction Act’s IRA focus on pharmaceutical manufacturers ignored a key player in the pharmaceutical supply chain — the Pharmacy Benefit Manager.

In November of 2022, we predicted a fertile post-election congressional landscape for Pharmacy Benefit Manager (PBM) practice reform. Six months into the 118th Congress, we can confirm...

The Federal Trade Commission has altogether issued compulsory orders to the six-largest phamacy benefit managers and three affiliated group purchasing organizations.

The FDA’s expert advisers on neurological drugs will discuss the application for traditional approval for Leqembi, the second treatment for Alzheimer’s disease to reach the market.

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and

Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by President Donald Trump.

Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by then-President Donald Trump.

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration's push for lower drug prices at the pharmacy counter.